What is the recommended dosing of Caplyta (lumateperone) for adults, including adjustments for hepatic impairment, renal impairment, and elderly patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Caplyta Dosing

The recommended dosage of Caplyta (lumateperone) is 42 mg administered orally once daily with or without food, with no titration required. 1

Standard Dosing

  • 42 mg once daily (oral administration)
  • Can be taken with or without food
  • No dose titration necessary 1

Dose Adjustments for Drug Interactions

When Caplyta is coadministered with CYP3A4 inhibitors, dose reduction is mandatory:

  • Strong CYP3A4 inhibitors: Reduce to 10.5 mg once daily 1
  • Moderate CYP3A4 inhibitors: Reduce to 21 mg once daily 1

Hepatic Impairment

For patients with moderate or severe hepatic impairment (Child-Pugh class B or C), reduce the dose to 21 mg once daily. 1

  • Mild hepatic impairment (Child-Pugh A): No dose adjustment required
  • Moderate to severe hepatic impairment (Child-Pugh B or C): 21 mg once daily

Renal Impairment

The FDA label does not specify dose adjustments for renal impairment, suggesting that standard dosing (42 mg once daily) can be used across all levels of renal function. This is consistent with lumateperone's primary hepatic metabolism rather than renal clearance.

Elderly Patients

No specific dose adjustment is recommended for elderly patients in the FDA labeling. However, elderly patients with dementia-related psychosis should not receive Caplyta due to increased mortality risk 1. The standard 42 mg dose applies to elderly patients being treated for approved indications (schizophrenia or bipolar depression).

Important Safety Considerations

  • Caplyta carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis 1
  • Monitor all patients for suicidal thoughts and behaviors, particularly during initial treatment 1
  • The medication is contraindicated in patients with hypersensitivity to lumateperone 1

Available Formulations

Caplyta capsules are available in three strengths to accommodate dose adjustments 1:

  • 42 mg (blue cap/white body)
  • 21 mg (white cap/white body)
  • 10.5 mg (light pink cap/light pink body)

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.